selectivity and also performed mutagenicity studies. Proof of concept, in vivo studies, was conducted with two of the most promising derivatives (77 and 80). They were identified as candidates because they have (i) very simple and cost-effective syntheses; (ii) activity against different stages and strains of the parasite showing excellent in vivo behavior during the acute phase of Chagas disease; and
由克鲁斯锥虫寄生虫引起的恰加斯病已在数千年前被描述过。目前,它影响到数以百万计的人,其中大多数在拉丁美洲,并且没有合适的药物来治疗它。为了找到合适的药物来解决这个问题,我们在这里报告了82种新化合物的设计,合成和表征。体外锥虫杀灭行为显示出超过20种具有抗克氏锥虫活性的杰出衍
生物。此外,我们研究了对哺乳动物细胞的非特异性毒性,从而确定了它们的选择性,并进行了致突变性研究。使用两种最有希望的衍
生物(77和80进行了体内研究的概念验证))。之所以将它们确定为候选者,是因为它们具有(i)非常简单且具有成本效益的综合方法;(ii)在恰加斯病急性期期间,针对不同阶段和种类的寄生虫的活性表现出优异的体内行为;(iii)非特异性毒性或诱变活性。